CN113423402A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN113423402A
CN113423402A CN202080013784.5A CN202080013784A CN113423402A CN 113423402 A CN113423402 A CN 113423402A CN 202080013784 A CN202080013784 A CN 202080013784A CN 113423402 A CN113423402 A CN 113423402A
Authority
CN
China
Prior art keywords
erdatinib
cancer
treatment
daily
serum phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080013784.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·奥哈根
P·M·Z·德波雷
A·N·阿瓦达尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN113423402A publication Critical patent/CN113423402A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080013784.5A 2019-02-12 2020-02-11 癌症治疗 Pending CN113423402A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806.2 2019-02-12
EP19156806 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (1)

Publication Number Publication Date
CN113423402A true CN113423402A (zh) 2021-09-21

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013784.5A Pending CN113423402A (zh) 2019-02-12 2020-02-11 癌症治疗

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (1) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
US20240058352A1 (en) * 2020-12-11 2024-02-22 Erasca, Inc. Combination therapies for the treatment of cancer
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170260168A1 (en) * 2015-10-23 2017-09-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200177T1 (it) * 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170260168A1 (en) * 2015-10-23 2017-09-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOAQUIM BELLMUNT等: "Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 28, no. 11, 10 April 2010 (2010-04-10), XP055646394, DOI: 10.1200/JCO.2009.25.4599 *

Also Published As

Publication number Publication date
SG11202107850VA (en) 2021-08-30
AU2020223467A1 (en) 2021-08-05
AU2020223467B2 (en) 2025-12-04
IL285466A (en) 2021-09-30
JP2022521173A (ja) 2022-04-06
WO2020165181A1 (en) 2020-08-20
US20220168298A1 (en) 2022-06-02
TWI863962B (zh) 2024-12-01
KR20210126654A (ko) 2021-10-20
JOP20210216A1 (ar) 2023-01-30
PH12021551949A1 (en) 2022-07-18
MA54932A (fr) 2021-12-22
EP3923942A1 (en) 2021-12-22
TW202045173A (zh) 2020-12-16
BR112021015686A2 (pt) 2021-10-26
MX2021009670A (es) 2021-09-08
CA3126959A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
TWI798199B (zh) 癌症治療
JP7668777B2 (ja) 癌治療
TWI734734B (zh) 一種ｅｇｆｒ/ｈｅｒ２受體酪氨酸激酶抑制劑在製備治療ｈｅｒ２突變癌症藥物中的用途
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
TWI863962B (zh) 癌症治療
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
HK40013982A (en) Cancer treatment
HK40103983A (en) Cancer treatment
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination